Is There Merit for MET-Targeted Therapies in Gastroesophageal Cancer?

Massimiliano Mazzone^{1

2}, Veronica Finisguerra^{3

4}, Hans Prenen^{2

5}

Affiliations

¹ Laboratory of Tumor Inflammation and Angiogenesis, Center for Cancer Biology, Vlaams Instituut voor Biotechnologie, Leuven, Belgium.
² Laboratory of Tumor Inflammation and Angiogenesis, Center for Cancer Biology, Department of Oncology, Catholic University Leuven, Leuven, Belgium.
³ Ludwig Institute for Cancer Research, Brussels, Belgium.
⁴ De Duve Institute, Université Catholique de Louvain, Brussels, Belgium.
⁵ Division of Gastroenterology-Hepatology, University Hospitals Gasthuisberg, Leuven, Belgium.

Comment

Massimiliano Mazzone et al. JAMA Oncol. 2018.

. 2018 Jan 1;4(1):131-132.

doi: 10.1001/jamaoncol.2017.2725.

Massimiliano Mazzone^{1

2}, Veronica Finisguerra^{3

4}, Hans Prenen^{2

5}

¹ Laboratory of Tumor Inflammation and Angiogenesis, Center for Cancer Biology, Vlaams Instituut voor Biotechnologie, Leuven, Belgium.
² Laboratory of Tumor Inflammation and Angiogenesis, Center for Cancer Biology, Department of Oncology, Catholic University Leuven, Leuven, Belgium.
³ Ludwig Institute for Cancer Research, Brussels, Belgium.
⁴ De Duve Institute, Université Catholique de Louvain, Brussels, Belgium.
⁵ Division of Gastroenterology-Hepatology, University Hospitals Gasthuisberg, Leuven, Belgium.

No abstract available

Comment on

Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma: The METGastric Randomized Clinical Trial.
Shah MA, Bang YJ, Lordick F, Alsina M, Chen M, Hack SP, Bruey JM, Smith D, McCaffery I, Shames DS, Phan S, Cunningham D. Shah MA, et al. JAMA Oncol. 2017 May 1;3(5):620-627. doi: 10.1001/jamaoncol.2016.5580. JAMA Oncol. 2017. PMID: 27918764 Free PMC article. Clinical Trial.